Literature DB >> 10955369

Assessment of coagulation and platelet activation in coronary sinus blood induced by transcatheter coronary intervention for narrowing of the left anterior descending coronary artery.

O Mizuno1, Y Hojo, U Ikeda, T Katsuki, H Fukazawa, K Kurosaki, H Fujikawa, K Shimada.   

Abstract

Influences of recently developed methods for coronary intervention on hemostasis in the coronary circulation are unclear. The objective of this study was to investigate changes in coagulation and platelet activation in the coronary circulation induced by percutaneous transluminal coronary angioplasty (PTCA). We studied 35 patients with coronary heart disease who underwent elective PTCA to isolated stenotic narrowing of left coronary arteries. Seven patients received only PTCA, 12 underwent percutaneous transluminal rotational atherectomy (PTRA), and 16 underwent stent implantation. Blood samples were drawn from the coronary sinus immediately before and after as well as 4 and 24 hours after PTCA. Plasma levels of tissue factor (TF), thrombin-antithrombin III complex, plasminogen activator inhibitor (PAI)-1, tissue plasminogen activator (t-PA), beta-thromboglobulin, and platelet factor 4 were measured by enzyme-linked immunosorbent assay. In all patients, TF levels in the coronary sinus blood showed significant increases 4 and 24 hours after PTCA and thrombin-antithrombin III complex levels showed significant increases 24 hours after PTCA. PAI-1 showed significant increases 24 hours after PTCA and t-PA showed significant increases 4 and 24 hours after PTCA. Changes in levels of these markers by PTCA were similar among the 3 groups. In PTRA, levels of beta-thromboglobulin and platelet factor 4, markers of platelet activation, increased immediately after the procedure and returned to baseline levels after 4 hours. PTCA induced increases in blood coagulation and fibrinolysis in the coronary circulation. PTRA caused a marked but transient activation of platelets. These changes may contribute to acute complications during the procedure.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10955369     DOI: 10.1016/s0002-9149(99)00651-7

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Effects of diltiazem on platelet activation and cytosolic calcium during percutaneous transluminal coronary angioplasty.

Authors:  H Dai; J Chen; Q Tao; J Zhu; F Zhang; L Zheng; Y Qiu
Journal:  Postgrad Med J       Date:  2003-09       Impact factor: 2.401

2.  Platelet reactivity in coronary ostial blood: a reflection of the thrombotic state accompanying plaque rupture and of the adequacy of anti-thrombotic therapy.

Authors:  S S Kabbani; M W Watkins; P A Holoch; E F Terrien; B E Sobel; D J Schneider
Journal:  J Thromb Thrombolysis       Date:  2001-10       Impact factor: 2.300

3.  Inhibition of the tissue factor pathway of coagulation by recombinant nematode anticoagulant protein c2 during elective coronary stent implantation.

Authors:  A H M Moons; N R Bijsterveld; K T Koch; J C M Meijers; J G P Tijssen; T van der Poll; H R Büller; R J G Peters
Journal:  Neth Heart J       Date:  2004-02       Impact factor: 2.380

Review 4.  Inflammatory and thrombotic mechanisms in coronary atherosclerosis.

Authors:  D Tousoulis; G Davies; C Stefanadis; P Toutouzas; J A Ambrose
Journal:  Heart       Date:  2003-09       Impact factor: 5.994

5.  Circulating soluble lectin-like oxidized low-density lipoprotein receptor-1 levels predict percutaneous coronary intervention-related periprocedural myocardial infarction in stable patients undergoing elective native single-vessel PCI.

Authors:  Mehmet Balin; Ahmet Celik; M Ali Kobat; Adil Baydas
Journal:  J Thromb Thrombolysis       Date:  2012-11       Impact factor: 2.300

6.  Gensini score values for predicting periprocedural myocardial infarction: An observational study analysis.

Authors:  Yao Wang; Qingbo Lv; Ya Li; Songzan Chen; Liding Zhao; Guosheng Fu; Wenbin Zhang
Journal:  Medicine (Baltimore)       Date:  2022-07-22       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.